A phase I study to evaluate safety and antitumor activity of biweekly BMS-936558 (Anti-PD-1, MDX-1106/ONO-4538) in patients with RCC and other advanced refractory malignancies.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Clinical Oncology

• Publication date

  2011-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.2011.29.7_SUPPL.331PMID 27968606
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity

  2020cites this paper
• Cancer immunotherapy and application of PPRHs for PD-L1 silencing in lymphomas

  2016cites this paper
• Inhibitory immunologicznych punktów kontrolnych podziału komórki w leczeniu chorób nowotworowych

  2016cites this paper
• Synergistic antitumor responses by combined GITR activation and sunitinib in metastatic renal cell carcinoma

  2016cites this paper
• Immune Checkpoint Inhibitors (Anti-CTLA4, Anti-PD-1) in RCC

  2015cites this paper
• Emerging tyrosine kinase inhibitors for the treatment of renal cancer

  2015cites this paper
• A novel personalized vaccine approach in combination with targeted therapy in advanced renal cell carcinoma.

  2014cites this paper
• T Cell Co-regulatory Signals and Their Role in Cancer Therapy

  2014cites this paper
• Clinical outcomes and survival of advanced renal cancer patients in phase I clinical trials.

  2014cites this paper
• Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma.

  2013cites this paper
• A new age for vaccine therapy in renal cell carcinoma.

  2013cites this paper
• Tumor Infiltrating PD1-Positive Lymphocytes and the Expression of PD-L1 Predict Poor Prognosis of Soft Tissue Sarcomas

  2013cites this paper
• Novel Immunotherapies in GU Malignancies

  2013cites this paper
• Advances in the systemic treatment of metastatic melanoma.

  2013cites this paper
• Immune therapy for kidney cancer: a second dawn?

  2013cites this paper
• Anti-Programmed Death 1 (PD1)

  2013cites this paper
• Role of the PD‐1 Pathway in the Immune Response

  2012cites this paper
• The Evolv ing Landscape of Metastat ic Renal Cel l Carc inoma

  2012cites this paper
• The blockade of immune checkpoints in cancer immunotherapy

  2012cites this paper
• Emerging Agents in Renal Cell Carcinoma

  2012cites this paper
• Emerging immunotherapies for renal cell carcinoma.

  2012cites this paper
• Coinhibitory molecules in hematologic malignancies: targets for therapeutic intervention.

  2012cites this paper
• Systemic therapy in renal cell carcinoma: advancing paradigms.

  2012cites this paper
• The expression, function, and clinical relevance of B7 family members in cancer

  2012cites this paper
• Molecular Pathways: Next-Generation Immunotherapy—Inhibiting Programmed Death-Ligand 1 and Programmed Death-1

  2012cites this paper
• Novel Therapies for Metastatic Renal Cell Carcinoma: Efforts to Expand beyond the VEGF/mTOR Signaling Paradigm

  2012cites this paper
• The evolving landscape of metastatic renal cell carcinoma.

  2012cites this paper
• Novel agents and approaches for advanced renal cell carcinoma.

  2012cites this paper
• Developing Cancer Immunotherapies by the manipulation of Immune Checkpoints

  2012cites this paper
• Cancer immunotherapy comes of age

  2011cites this paper
• Blockade of the B7-H1/PD-1 Pathway for Cancer Immunotherapy

  2011cites this paper
• Role of immunotherapy for renal cell cancer in 2011.

  2011cites this paper
• Immunotherapy for prostate cancer: biology and therapeutic approaches.

  2011cites this paper
• Cancer immunotherapy comes of age.

  2011cites this paper